Condition: Dengue · Sponsor: Novartis Pharmaceuticals
The purpose of this study is to characterize the effect on dengue viral load, fever clearance time as well as on clinical signs and symptoms with the treatment of EYU688 compared with placebo in patients with dengue fever.
This description comes directly from the study's public registry record.
Novartis Pharmaceuticals · +41613241111 · novartis.email@novartis.com
Novartis Pharmaceuticals
Always discuss trial participation with your own doctor first.
| Novartis Investigative Site | Manaus, Amazonas, Brazil | Recruiting |
| Novartis Investigative Site | Brasília, Federal District, Brazil | Recruiting |
| Novartis Investigative Site | Rio de Janeiro, Rio de Janeiro, Brazil | Recruiting |
| Novartis Investigative Site | Rio Grande, Rio Grande do Sul, Brazil | Recruiting |
| Novartis Investigative Site | Sorocaba, São Paulo, Brazil | Recruiting |
| Novartis Investigative Site | Sao Jose Rio Preto, Brazil | Recruiting |
| Novartis Investigative Site | Barranquilla, Atlántico, Colombia | Withdrawn |
| Novartis Investigative Site | Bucaramanga, Santander Department, Colombia | Withdrawn |
| Novartis Investigative Site | Cali, Valle del Cauca Department, Colombia | Recruiting |
| Novartis Investigative Site | Belagavi, Karnataka, India | Recruiting |
| Novartis Investigative Site | Mumbai, Maharashtra, India | Withdrawn |
| Novartis Investigative Site | Pune, Maharashtra, India | Recruiting |
+ 12 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06006559